Since JQ1 and other (similar) BET bromodomain inhibitors are considered to be used in clinical trials in AML patients in combination with conventional cytostatic drugs like ARA-C, we asked whether JQ1 and ARA-C would produce cooperative or even synergistic growth-inhibitory effects on AML cells. The gene discussed is DNER; the disease is acute myeloid leukemia.